Key Drivers
- High gross margin
- Large cash balance
- Persistent negative FCF
AIAI Summary
Legend has transitioned into a commercially driven, execution-sensitive investment where near-term valuation hinges on CARVYKTI adoption, manufacturing yield improvements (reduce 6–9% out-of-spec rates) and free-cash-flow inflection—monitor unit throughput, outpatient dosing mix, and FCF weekly as small slippage can rapidly reintroduce funding and dilution risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Large cash balance
- •Persistent negative FCF
Legg Mason: strong gross margin and cash runway contrast with large R&D/SG&A–driven operating losses, negative FCF and recurring negative profitability despite modest debt and market pricing for recovery.
Price Behavior
Key Price Behavior Insights:
- •Downtrend continuation
- •Near-term support
- •Resistance band above
LEGN is in a short-term downtrend, falling about 14% over the last month to a 21-day low at $17.41, sitting on $17.4–$17.9 support and vulnerable to a mean-reversion bounce but needing a break above $19.5–$20.3 to shift sellers' control.
~14% drop from $20.27 to $17.41 over the last month
Sentiment & News
Key News Insights:
- •Mixed flows
- •Earnings released
- •Artisan accumulation
Legend Biotech reported FY2025 results while institutional activity was mixed—Artisan added heavily as Capital International and ArrowMark trimmed positions.
Mixed institutional moves amid the earnings release suggest short-term share volatility but no clear directional signal for LEGN's medium-term trend
Similar Companies in Healthcare
Other companies in the same sector with AI ratings